Introduction
============

*TP53* is well known as the most commonly mutated gene in human cancer \[[@b1]\]. The gene product is a 53-kD phosphoprotein of 393 amino acids, forming five highly conserved regions and four functional domains \[[@b2]\]. In response to a stress signal, the p53 protein is activated by post-translational modifications. These modifications stabilize p53, intracellular levels rise and p53 is activated as a transcription factor to direct stress-specific transcriptional response programs, leading to cell cycle arrest, cell senescence or apoptosis. p53 acts as a central node in the cellular network of stress responses, with multiple divergent inputs that regulate p53 activity and multiple outputs from activated p53 \[[@b3]\]. The mutations of *TP53* gene seen in human cancers result in an inactive protein which is unable to initiate appropriate stress responses, leading to both enhanced tumouri-genic potential and impaired responses to therapeutic agents. In addition to mutations in the *TP53* gene coding sequence, p53 activity may also be decreased by alterations of genes that act as regulators of p53 activity. MDM2 is one major regulator, which degrades p53 and the importance of this regulatory pathway is underscored by the observation of overexpression of MDM2 by gene amplification in a significant proportion of human cancers \[[@b5]\]. The ability of another member of the p53 family, p73, to interact with and partially compensate for loss of p53 activity is another emerging factor of importance for p53 function and has been suggested to be important for tumour response to some genotoxic therapies \[[@b6]\].

It is therefore conceivable that the existence of natural variants of p53 and other proteins that influence p53 activity could be linked with the development of tumours in the human population and could represent predictive biomarkers for preventive and early intervention strategies. A total of 38 polymorphisms in the *TP53* gene are referred to in SNP500 Cancer Database \[[@b7]\] (<http://snp500cancer.nci.nih.gov/home_1.cfm>). Most of these natural variants are localized in introns, although polymorphisms also exist in exons of *TP53*. Some of these *TP53* polymorphisms have been analysed in large populations ([Fig. 1](#fig01){ref-type="fig"}) whereas other polymorphisms have been described rarely and their significance remains to be determined. In addition, polymorphisms in genes that regulate p53 or are regulated by p53 have been described. Here, we review the evidence that polymorphisms in the p53 pathway are important determinants of cancer predisposition in the human population.

![*TP53*, *TP63* and *TP73* gene structure and the positions of the most important polymorphisms.](jcmm0013-0440-f1){#fig01}

SNPs in *TP53* exons altering amino-acid sequence
=================================================

The substitution of proline (codon CCG) to serine (codon TCG) at residue 47 (P47S), and the substitution of arginine (codon CGC) to proline (codon CCC) at residue 72 (R72P), both localized in exon 4, are among the most intensively studied polymorphisms found in the coding regions of *TP53* which alter the amino-acid sequence. Felley-Bosco *et al.* first identified single nucleotide polymorphism (SNP) P47S and found that polymorphic variant S47 is very rare in African Americans and undetectable in Caucasians \[[@b8]\]. *In vitro* studies have shown that the S47 variant is not as good a substrate for the nearby phosphorylation at S46 by p38 mitogen-activated protein kinase (MAPK) and has impaired pro-apoptotic ability due to a decreased transcriptional activation of p53AIP1 and p53-upregulated modulator of apoptosis (PUMA) \[[@b9]\]. Although these data suggest that individuals with this polymorphism will be at higher risk for tumour development and have a relatively impaired response to therapy, there are as yet no firm data in large population studies that confirm these suggestions, partly due to the rarity of the polymorphism.

The codon R72P SNP results in a structural change of the protein \[[@b10]\]. Further, this polymorphism in exon 4 is located in the proline-rich domain, which was shown to be important for the apoptotic function of p53 ([Table 1](#tbl1){ref-type="table"}) \[[@b12]\]. A significant difference in P72 allele frequency was found between a Nigerian population (African Black) and a Swedish population (Western Europe), which were 17% and 63%, respectively. In contrast, no difference was found between populations living on the same geographical latitude \[[@b13]\]. This variation in frequency from the equator to higher latitudes suggests a selection pressure upon these two forms of p53 protein. By comparison with chimpanzee DNA, it is evident that the P72 allele is the older allele, currently present at a higher frequency in Africa, while the R72 allele arose later in Caucasians and Asians.

###### 

The roles of R72P polymorphism in cancer

  Phenomenon                                                                            p53 status                                                                                                                                           Mechanism                                                                                                                                    Ref.
  ------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Apoptosis                                                                             Wt Wt                                                                                                                                                The R72 allele correlates with more efficient induction of apoptosis compared to the P72 variant.                                            \[[@b15]\]
  Degradation                                                                                                                                                                                                                                R72 allele has greater capacity to interact with MDM2.                                                                                       \[[@b15]\]
  R72 was found more efficiently targeted for degradation by the E6 protein of HPV16.   \[[@b22]\]                                                                                                                                                                                                                                                                                        
  Gain of function                                                                      mut                                                                                                                                                  The R72 allele is preferentially mutated and these mutants confer stronger affinity for interaction with p73 followed by its inactivation.   \[[@b16]\]
  Response to chemotherapy                                                              Wt                                                                                                                                                   R72 allele cases have higher response rates and longer survival than those with P72.                                                         \[[@b20]\]
                                                                                        P72 variant is more frequent and tumours are less sensitive to apoptosis-inducing treatment.                                                         \[[@b32]\]                                                                                                                                   
  mut                                                                                   Cancers expressing R72 mutants have lower response rates than those expressing P72 mutants.                                                          \[[@b16]\]                                                                                                                                   
                                                                                        R72 mutants tend to confer resistance to anticancer drugs, but it is not an universal phenomenon and depends on the mutation and drug utilization.   \[[@b128]\]                                                                                                                                  
  Reparation                                                                            Wt                                                                                                                                                   P72 is more efficient than R72 in specifically activating several p53-dependent DNA-repair target genes.                                     \[[@b21]\]

Several lines of evidence indicate that this polymorphism can play a role in apoptosis and cancer formation in humans. This is supported by observations that iASPP, a specific cellular inhibitor of p53 that binds to this proline-rich domain of p53, interacts more strongly with the P72 variant leading to inhibition of apoptosis \[[@b14]\]. In contrast, Dumont *et al.* showed that stronger interaction of the R72 variant with the nuclear-export protein CRM1 leads to enhanced nuclear export and accumulation in mitochondria resulting in release of cytochrome c into the cytosol \[[@b15]\]. Additionally they suggested that the R72 form had a higher affinity for MDM2 than the P72 form resulting in enhanced ubiquitination by this ubiquitin ligase \[[@b15]\]. The ability of mutant p53 proteins to bind p73 and inhibit its apoptotic activity in tumours is another important factor ([Table 1](#tbl1){ref-type="table"}). Interestingly, it seems that the interaction of p53 with p73 is influenced by a common *TP53* R72P polymorphism, since the binding of mutant p53 with R72 variant is stronger in comparison with the P72 variant and generates mutants with strong 'gain of function'\[[@b16]\]. Moreover Marin *et al.* reported a higher frequency of *TP53* mutations on the R72 allele compared with the P72 allele in different squamous cell cancers \[[@b17]\]. This proposal is supported by Tada *et al.*, who analysed mutations on the R72 allele in tumours from different tissues. Interestingly, they found a preferential selection of the R72 allele in cancers with recessive *TP53* mutants (mutants that do not inactivate wild-type *TP53* in a dominant negative manner). It was suggested that recessive *TP53* mutants achieve a selective growth advantage by an R72-dependent inactivation of *TP73*, whereas the dominant negative *TP53* mutants inactivate the remaining wild-type *TP53* allele in an R72-independent manner \[[@b18]\]. Additional report indicate that ovarian cancer patients with the P72 allele and non-missense sequence variants or missense sequence variants affecting L2 or L3 of the p53 protein have significantly poorer disease-specific survival compared to those with wild-type or other sequence \[[@b19]\]. This is tightly linked with the fact that the two allelic forms of mutant p53 confer different cellular resistance to anticancer agents, linking that effect to the outcome of chemotherapy in carcinomas expressing mutant p53 ([Table 1](#tbl1){ref-type="table"}) \[[@b16]\]. However, the *in vitro* response of cells exposed to anticancer agents is strongly influenced by this SNP in wild-type p53 as well \[[@b20]\]. To address the *in vivo* biological significance of the different molecular properties of the R72 and P72 variants, the responses of a well-defined series of patients with head and neck cancer to chemo-radiotherapy regimens were analysed. In this cohort of patients, the response rates and the survival (both overall and progression free) were significantly higher in cases retaining a wild-type p53 R72 allele \[[@b20]\]. The wild-type p53 P72 variant transcriptionally activates several p53-dependent target genes involved in DNA repair better than the p53 R72 form \[[@b21]\]. Concomitantly, cells expressing the p53 P72 form were able to repair DNA damage much more efficiently than the p53 R72-expressing cells.

In other work, Storey *et al.* presented results indicating that p53 R72 is significantly more susceptible to degradation by the high-risk HPV (human papillomavirus) E6 protein in comparison with p53 P72 \[[@b22]\]. Further small-scale population analysis of women in Italy revealed that this increased susceptibility to degradation by E6 is associated with higher incidence of cervical cancer in HPV-infected women who were homozygous for the R72 variant \[[@b22]\]. Although there have been several reports worldwide, the question whether \[[@b23]\] or not \[[@b24]\] p53 R72P polymorphism represents a significant risk factor in the development of cancer associated with HPV remains uncertain.

A number of studies have attempted to determine if there is an association between codon 72 polymorphic variants of *TP53* and increased risk for particular types of cancer ([Table 2](#tbl2){ref-type="table"}). These studies vary in their conclusions, as some report increased risk associated with the P72 allele for certain cancer types and others fail to show any significant associations. For example, a strong association between the R/R genotype and breast cancer was reported in Turkish patients \[[@b27]\]. Similarly, Langerod *et al.* reported association of R72 allele with *TP53* somatic mutations resulting in a growth advantage of breast carcinoma cells with this allele in a Norwegian population \[[@b28]\], and Kalemi et al.reported the R/R genotype as a risk factor for breast cancer in a Greek population \[[@b29]\]. In contrast, Tommiska *et al.* as well as Khadang *et al.* did not observe any association between *TP53* codon 72 variants and breast cancer risk \[[@b30]\]. These discrepancies can be explained by suggesting a more complex role of p53 R72P polymorphism in carcinogenesis. On the one hand, owing to R72 possessing a more potent apoptotic activity in comparison to P72, individuals with this SNP will have higher cancer susceptibility compared to those carrying R72. On the other hand, in tumours with p53 mutations, mutant p53 encoded by the R72 allele may bind to and inhibit p73 pro-apoptotic activity. Therefore, in tumours with wild-type p53 the P72 variant is more frequent and tumours are less sensitive to apoptosis-inducing treatment, whereas the R72 variant exerts its effects mainly in tumours with p53 mutations. This proposal is supported by studies of head and neck tumours bearing p53 mutations, with the R72 allele conferring resistance to chemotherapy and leading to shorter time of survival \[[@b32]\]. Additional reasons for these discrepancies could be that the biological impact of this SNP is influenced by other important factors, such as heterogeneity of p53 mutations, tissue specificity and genetic background, that act together with other unidentified factors in the selection process. For example, several epidemiological studies have reported an association between the presence of a P/P genotype and the risk for lung adenocarcinoma development \[[@b33]\]. Interestingly, an R/R genotype confers increased risk of squamous cell carcinoma in individuals deficient in a metabolizing enzyme involved in the detoxification of tobacco carcinogens \[[@b34]\]. This is consistent with the preferential mutation of the p53 R72 allele found in squamous tumours \[[@b17]\]. On the basis of these studies, it can be argued that the presence of a P/P genotype affects overall lung cancer development because of its poorer apoptotic properties. However, the absence of detoxifying enzymes may lead to a longer exposure to active carcinogens and the selection for mutant p53 that carries the R72 polymorphism, which would more effectively block the p73 safeguard apoptotic function \[[@b36]\].

###### 

Discussed *TP53* polymorphisms in cancer epidemiology

  Polymorphism of *TP53* gene   Cancer                Population / other comments   Allele or Genotype                                            Association with cancer risk / OR (95% CI)   Ref.
  ----------------------------- --------------------- ----------------------------- ------------------------------------------------------------- -------------------------------------------- ------------
  **R72P**                                                                                                                                                                                     
                                Breast                Finnish                                                                                     No                                           \[[@b30]\]
                                                                                    Familial: 0.94 (0.80--1.09)                                                                                
                                                                                    Unselected: 0.96 (0.82--1.12)                                                                              
                                Iranian                                             No                                                            \[[@b31]\]                                   
                                                      /                             1.1 (0.84--1.44)                                                                                           
                                Greek                 RR                            Yes                                                           \[[@b29]\]                                   
                                                      /                             6.66 (2.63--16.9) (*P*= 0.0001)                                                                            
                                Turkish               RR                            Yes                                                           \[[@b27]\]                                   
                                                                                    3.05 (1.19--7.8)                                                                                           
                                                                                    (P = 0.017)                                                                                                
                                Chinese               R                             Yes                                                           \[[@b21]\]                                   
                                                      /                             (*P* \< 0.001)                                                                                             
                                Japanese              PP                            Yes                                                           \[[@b129]\]                                  
                                ER positive                                         2.04 (*P*= 0.04)                                                                                           
  Cervical                      Peruvian                                            No                                                            \[[@b25]\]                                   
                                Japanese                                            No                                                            \[[@b26]\]                                   
                                Portuguese            /                             No                                                            \[[@b24]\]                                   
                                Indian                RR                            Yes                                                           \[[@b23]\]                                   
                                                                                    2.59 (1.18--5.67) (*P*= 0.038)                                                                             
  SCCHN                         non-Hispanic whites                                 No                                                            \[[@b38]\]                                   
                                                      //                            1.04 (0.75--1.44)                                                                                          
  Lung                          Caucasian             RP PP                         Yes                                                           \[[@b60]\]                                   
                                                      /                             1.34 (1.03--1.74) 1.47 (0.90--2.40)                                                                        
                                Japanese              PP                            Yes                                                           \[[@b130]\]                                  
                                                                                    2.2 (1.3--3.9)                                                                                             
                                                                                    (*P*= 0.005)                                                                                               
  Glioma                        Portuguese                                          No                                                            \[[@b41]\]                                   
                                                                                    1.07 (0.66--1.72) (*P*= 0.765)                                                                             
                                American              P                             Yes                                                           \[[@b131]\]                                  
                                                                                    (*P* \< 0.001)                                                                                             
  PIN3 Ins 16bp                                                                                                                                                                                
                                Breast                Unknown                       /                                                             No                                           \[[@b50]\]
                                Portuguese            A2A2                          Yes Familial: 4.4 (1.60--12.00) Sporadic: 3.88 (1.18--12.8)   \[[@b49]\]                                   
  Blader                        American                                            No                                                            \[[@b52]\]                                   
  Gastric                       Korean                                              No                                                            \[[@b51]\]                                   
                                                                                    (*P*= 0.1659)                                                                                              
  Ovarian                       German                A2A2                          Yes 8.64 (2.97--25.16)                                        \[[@b48]\]                                   
  Lung                          Caucasian             A1/A2 A2/A2                   Yes 1.59 (1.17--2.15) 1.63 (0.72--3.72)                       \[[@b60]\]                                   
  PIN6 G13494A                                                                                                                                                                                 
                                Breast                Caucasian                                                                                   No                                           \[[@b54]\]
  Ovarian                       German                                              Yes                                                           \[[@b53]\]                                   
                                                                                    1.93 (1.27--2.91)                                                                                          
  Ovarian                       Caucasian                                           Yes                                                           \[[@b54]\]                                   
  PIN6 G13964C                                                                                                                                                                                 
                                Breast                Australian                                                                                  No                                           \[[@b57]\]
                                Poland                                              No                                                            \[[@b58]\]                                   
                                American                                            Yes                                                           \[[@b56]\]                                   
                                                                                    (*P*= 0.0003)                                                                                              

While correlations between cancer risk and the codon 72 polymorphism are somewhat inconsistent, there are much firmer associations with cancer progression, age of onset, overall survival, etc. For example, survival analysis of 888 unselected breast cancer patients revealed that patients with P72 homozygous genotype had significantly poorer survival than patients with other genotypes (*P***=** 0.003). This effect on survival was independent of p53 expression in the tumours and multivariate analysis showed that P72 homozygous genotype was overall an independent prognostic factor (risk ratio of death, 2.1; 95% CI, 1.4--3.3; *P***=** 0.001) \[[@b30]\].

Interestingly, a recent study analysed 93 patients diagnosed with Hereditary Nonpolyposis Colorectal Cancer; these individuals had germline mutations in the mismatch repair genes MLH1 or MSH2. Individuals with at least one copy of the P72 allele had a median age of onset for disease 13 years earlier than individuals who were homozygous for the R72 allele \[[@b37]\]. Analyses by other groups have revealed an 11 year earlier age of onset in individuals with at least one P72 allele for oral cancer, and a 6-year earlier age of onset for squamous carcinoma of the head and neck \[[@b38]\]. These trends may be explained by the increased apoptotic potential of the R72 variant, as well as the findings that individuals with the R/R genotype have higher response rates and better survival after receiving chemo- and radiation therapy for advanced head and neck cancer \[[@b20]\] and for cancers of the breast and lung \[[@b30]\]. These data are in contrast with recently published results of Lima-Ramos *et al.*, who determined the impact of R72P SNP on patient survival and therapeutic response in 171 glioma patients in Portugal. They did not observe an association of *TP53* R72P polymorphism with glioma risk and overall patient survival. However a significant association was observed in glioma patients harbouring the P72 allele and their response to adjuvant therapy \[[@b41]\].

Polymorphism in *TP53* introns
==============================

There is growing evidence that mechanisms of gene regulation, including mutations in enhancers, splice donor and acceptor sites of introns, and promoter elements, could play an important role in the regulation of gene expression, including p53 \[[@b42]\]. In particular, mutations in intron sequences may initiate aberrant pre-messenger RNA splicing, producing mRNA that may be translated into a defective protein. Furthermore, introns are often involved in regulation of gene expression and DNA-protein interactions and mutations in intron sequences may affect these functions. Therefore the identification of mutations in non-coding sequences that result in aberrant gene expression may provide useful tools for the detection of patients with risk of the development of cancer.

The IARC *TP53* Mutation Database lists 29 common polymorphisms in the non-coding region of *TP53*, of which a 16bp duplication in intron 3 localized at nucleotide 11951 (+16) \[[@b44]\], G to A transversion in intron 6 at nucleotide 13494 (G13494A) often reported as *MspI*\[[@b46]\] or *Bst*NI/N*ciI* polymorphisms \[[@b47]\] and a G to C transversion in intron 6 at nucleotide 13964 (G13964C) \[[@b44]\] have been suggested to impact on the function or level of expression of p53 to date. Studies of the association between these intronic polymorphisms and cancer predisposition have revealed inconsistent results. For example, although Runnebaum *et al.* noted an eightfold elevated risk for ovarian cancer in patients with the intron 3 variant \[[@b48]\] and Costa *et al.* suggest this polymorphism as a risk modifier in sporadic and familial breast cancer \[[@b49]\], other studies found no such association \[[@b50]\].

Clinical study of 310 German Caucasian ovarian cancer patients and 364 healthy controls for association of intron 6 G13494A polymorphism showed that the individuals who carried the rare *MspI* allele have an overall 1.93-fold increased risk (95% CI 1.27--2.91) of ovarian cancer \[[@b53]\]. Similarly Mavridou *et al.* described a statistically significant difference in the distribution of the G13494A polymorphism in intron 6 between healthy Caucasian control subjects and patients with ovarian cancer, but found no difference between control subjects and patients with breast cancer \[[@b54]\]. In contrast, in a small set of samples, Peller *et al.* reported a statistically significant association between the G13494A polymorphism and the risk of breast and colon cancers \[[@b55]\].

In case of G13964C polymorphism, Lehman et al. detected the rare C allele in 3 of 42 American hereditary breast cancer patients, compared to 0 of 171 control sporadic breast cancer patients \[[@b56]\]. Moreover, they demonstrated prolonged *in vitro* survival in response to cisplatin treatment in lymphoblastoid cell lines derived from the heterozygous GC patients and showed decreased chemotherapy-induced apoptosis \[[@b56]\]. Immunohistochemical analysis of breast tumours from these patients revealed high levels of mutant p53 protein, suggesting a functional mutation in the *TP53* gene. However, contradictory data were reported by Marsh et al., who found the G and C variants at the same frequency in Australian hereditary breast (ovarian) cancer syndrome patients (3/71) and in healthy control individuals (5/143) \[[@b57]\]. Similarly, there was no evidence of the association of the 13964C variant with a high risk of cancer development in a series of Polish cancer families previously screened for germline mutations in p53 \[[@b58]\].

Linkage between the polymorphisms
=================================

Haplotype is a set of single nucleotide polymorphisms on a single chromatid that are statistically associated. Knowledge of the accumulated number of variants on the same chromosome may provide additional information about changes in p53 function because there could be additive or multiplicative changes in function. Interestingly, several studies have found that these polymorphisms in exon 4, introns 3 and 6 are in strong linkage disequilibrium. *In vitro* experiments revealed that cell lines with at least one variant allele at all three polymorphic sites had a statistically significantly reduced DNA repair capacity in comparison with cell lines with all wild-type alleles. It remains to be more precisely determined whether the effect of the combined polymorphisms occurs also *in vivo*, however, reduced DNA repair capacity and apoptotic responses have been linked to an increased risk of lung cancer \[[@b59]\]. Further it was also determined that the p53 hap-lotypes were associated with risk for lung \[[@b60]\], colorectal \[[@b63]\], breast \[[@b33]\] and other cancers \[[@b65]\].

Generally these data highlight the value of examining multiple polymorphisms in *TP53* gene, which could be critical for risk of developing tumours, risk of progression, and prognostic effects. For example, occurrence of the multivariant alleles from *TP53* exon 4 and intron 3 results in a significantly poorer prognosis in non-small cell lung cancer \[[@b67]\], and both *TP53* polymorphisms P72 and 16bp insertion are associated with higher incidence of lymph node metastases \[[@b49]\]. Further studies are needed to determine the mechanism by which exon 4 and introns 3 and 6 variants modify cancer risk.

Silent mutations and SNPs in *TP53*
===================================

Silent mutations are a potentially interesting group of *TP53* gene polymorphisms. These SNPs change one codon for another synonymous one, and for this reason do not affect the structure of the gene product. The predominant view is that these synonymous mutations are effectively neutral and consequently they play no role in carcinogenesis. Nevertheless it has been proposed that silent mutations are not necessarily neutral \[[@b68]\]. Silent mutations may affect the function of the gene in many different ways. The most classical view is related to the different usage of synonymous codons resulting in different translational rate \[[@b70]\]. Another possible explanation is that alterations in mRNA splicing are an important cause of genetic diseases, and in particular they are relatively common in cancer \[[@b72]\]. Point mutations may either destroy or create donor or acceptor splicing sites or alter mRNA folding which can influence splicing, processing or translational control and regulation. Splicing mutations that fall in splicing junctions (donor or acceptor sites) are relatively rare in *TP53*, accounting for less than 1% of the database \[[@b73]\]. In some cases the mutations altering the splicing site are silent, such as the case of the silent mutation at codon 125 of *TP53* (ACG→ACA), which has been experimentally demonstrated to generate aberrant transcripts \[[@b74]\]. Exonic splicing enhancers are the second type of splicing signals whose alteration is more likely to be associated with genetic disorders. Splicing enhancers are degenerate motifs located inside exons that are recognized by splicing factors that are critical for exonic recognition. Nucleotide mutations inside these motifs may disrupt splicing by directly inactivating the ability of the spliceosome machinery to recognize them, leading to exon skipping. It has been estimated that up to 50% of point mutations responsible for genetic diseases cause aberrant splicing \[[@b75]\]. It was shown that silent mutations, especially those mutations that were always found as singlet and never as a doublet or as a multiplet, tend to be preferentially located inside candidate exonic splicing enhancers motifs \[[@b68]\]. Moreover in *TP53*, all exonic CpG sequences are methylated. This epigenetic modification is correlated with frequent G:C→A:T transitions \[[@b78]\]. Interestingly, it was found that silent mutations are non-random, mostly involving G:C→A:T transitions (62%) as well \[[@b79]\]. It is also the case of the polymorphism in codon 36 (CCG→CCA) in *TP53* gene described by Felix *et al.*\[[@b80]\]. This polymorphism has been described in several publications; however, no association with a specific phenotype has been described so far.

Polymorphisms in other members of the p53 family
================================================

The discovery of the p53-related proteins p63 and p73, which are able to regulate the cell cycle and apoptosis after DNA damage, leads to evaluation of the status of a network that contains p53, p73 and p63 in predicting prognosis and response to chemotherapy.

p63 is actually the eldest evolutionary conserved member of the p53 family phylogenetically \[[@b81]\]. The *TP63* gene is commonly overexpressed in certain human cancers, but mutations are very rare. Inherited mutations cause various developmental syndromes of the cranio-facial and skeletal abnormalities \[[@b82]\], but polymorphisms that associate with cancer incidence have not been described. In tumours, mutant p53 can enhance p63 survival functions and inhibit p63 apoptotic functions in a mutant-specific manner, although the influence of the TP53R72P variant in this process has not been tested (unlike the effects on *TP73* noted below).

The human *TP73* gene is composed of 15 exons and its expression is complicated by the presence of at least seven alternatively spliced C-terminal isoforms and of at least four alternatively spliced N-terminal isoforms \[[@b83]\]. Extensive molecular analyses of p73 in various tumours suggested that mutations in the *TP73* gene are rare; however, loss of heterozygosity at the *TP73* locus has been reported at various frequencies in different tumours. Furthermore the expression of the *TP73* gene is commonly altered in human malignancies, implying that this gene may have important roles in tumourigenesis \[[@b84]\].

*TP73* gene can be transcribed from two distinct promoters, driving the expression of p53-like proteins containing the transac-tivation domain (TAp73), and proteins lacking TA, called ATAp73. The TAp73 isoforms are able to bind specifically to DNA through p53 response elements (RE) and activate transcription of target genes. Like p53, such activation can induce cell cycle arrest or apoptosis \[[@b83]\]. ANp73 acts as a potent transdominant inhibitor of TAp63, TAp73 and wild-type p53 \[[@b86]\]. Thus, theoretically, p73 expression can be either pro- or anti-oncogenic, depending on whether anti- or pro-apoptotic (ATAp73 or TAp73, respectively) isoforms are expressed. In keeping with the theory, there is evidence for oncogenic or tumour suppressor functions of *TP73* in different human tumours \[[@b87]\].

It is unknown whether the alteration of p73 expression has any genetic basis such as sequence variations or polymorphisms. At least 20 single-nucleotide polymorphisms have been identified in *TP73* (some in exons and others in introns), but none cause an amino acid change. Four polymorphisms have been suggested to alter *TP73* gene expression: a 73 bp deletion in intron 1 and three single nucleotide polymorphisms: two in exon 2 and one in promoter 3 ([Fig. 1](#fig01){ref-type="fig"}). Whereas the promoter 3 variant did not have a significant biological effect, there are several studies indicating that the two SNPs localized at position 4 (G to A) and 14 (C to T) in the 5'-untranslated region of exon 2 of *TP73* gene may be associated with an increased risk of certain types of cancer. These two polymorphisms are in complete linkage disequilibrium with one another and form a polymorphism referred to as the AT and GC alleles. This polymorphism lies upstream of the initiating codon AUG of exon 2, a region which may theoretically form a stemloop structure that could potentially affect gene expression through alteration of the efficiency of translation initiation \[[@b88]\]. To test the hypothesis that the *TP73* G4C14 to A4T14 polymorphism is associated with risk of cancers, several hospital based case-control studies have been done ([Table 3](#tbl3){ref-type="table"}). These studies provide evidence that *TP73*AT variant is significantly associated with an increased risk of squamous cell carcinoma of the head and neck (SCCHN), endometrial cancer and lung cancer \[[@b89]\]. On the other hand, some studies suggest that the AT variants possess a protective role against cancer development \[[@b92]\] and a study of 526 breast cancer patients showed an association of AT variant with long-term survival \[[@b94]\]. Although inconsistent, these results raise the possibility that analysis of *TP73* polymorphism may provide useful prognostic information for cancer patients. Nevertheless, additional independent studies are needed to confirm these findings.

###### 

Discussed *TP73* polymorphisms in cancer epidemiology

  Polymorphism                                                                                                                                                                                                                                                                                                                                                    Comments                                                                                                                                                                                                                                                                                                                                                                                                                     Ref.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  **G4C14 to A4T14**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Prognosis                                                                                                                                                                                                                                                                                                                                                       708 SCCHN patients and 1229 cancer-free controls. Genotypes (GC/AT + AT/AT) were associated with significantly increased risk for SCCHN (OR = 1.33, 95% CI = 1.10--1.60).                                                                                                                                                                                                                                                    \[[@b89]\]
  1054 lung cancer patients and 1139 cancer-free controls. Genotypes (GC/AT + AT/AT) were associated with significantly increased risk for lung cancer (OR = 1.32, 95% CI = 1.10--1.59).                                                                                                                                                                          \[[@b90]\]                                                                                                                                                                                                                                                                                                                                                                                                                   
  114 endometrial cancer patients and 442 controls. Association between the *TP73* AA genotype and an increased risk of endometrial cancer (OR = 2.82, 95% CI = 1.36--5.82).                                                                                                                                                                                      \[[@b91]\]                                                                                                                                                                                                                                                                                                                                                                                                                   
  Protective role of AT variant                                                                                                                                                                                                                                                                                                                                   84 oesophageal cancers (25 squamous and 59 adenocarcinoma) and 152 cancer-free controls.                                                                                                                                                                                                                                                                                                                                     \[[@b92]\]
  AT/AT homozygotes were less prevalent in the cancer population (1.2%) compared to controls (9.9%) (*P* \< 0.02), OR = 0.11 (95% CI = 0.02--0.6).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  425 lung cancer patients and 588 cancer-free controls. AT haplotypes were less common in the cancers (*P*= 0.0018). Compared to the *TP73* GC/GC homozygotes, both the AT/AT variant homozygotes and GC/AT heterozygotes were associated with significantly decreased risk (OR = 0.45, 95% CI = 0.26--0.80 and OR = 0.70, 95% CI = 0.53--0.92, respectively).   \[[@b93]\]                                                                                                                                                                                                                                                                                                                                                                                                                   
  Association with cancer risk                                                                                                                                                                                                                                                                                                                                    Study of 526 breast cancer patients with a median follow-up of 7.3 years.GC/GC genotype was associated with worse clinical outcome (*P*= 0.02).GC/GC genotype remained an independent indicator of poor prognosis (disease-free survival: HR = 1.82, *P*= 0.003 and overall survival: HR = 1.99, *P*= 0.004) in multivariate analysis.                                                                                       \[[@b94]\]
  Intron 1 del 73 bp                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                  Tumour and normal tissue from 81 colorectal cancer patients. 73 bp deletion was found in at least one allele in 40.7% of the patients, its presence was associated with advanced stages (*P*= 0.03), vascular invasion (*P*= 0.02), and lymph node metastases (*P*= 0.04). Statistical association was found between the presence of the deletion in hemi- or homozygosis and low levels of the TAp73 suppressor isoforms.   \[[@b96]\]
  45 colorectal and 43 breast cancer patients and 34 healthy controls. Allele with Intron 1 del 73 bp was significantly associated with increased risk of tumour (*P*= 0.045).                                                                                                                                                                                    \[[@b95]\]                                                                                                                                                                                                                                                                                                                                                                                                                   

A novel regulatory region of p73 expression has been identified in a 1 kb stretch of intron 1 upstream of the initiating ATG codon in exon 2. This region contains six sites for binding of the tran-scriptional repressor ZEB1 (δEF1), whose inhibition leads to increased expression of p73. Interestingly the 73 bp deletion in intron 1 is localized just between −489 and −417 of this negatively regulated fragment and was observed to be statistically more frequent in individuals with a diagnosis of breast or colorectal carcinomas compared to healthy controls \[[@b95]\]. An expression-based analysis of primary tumour material suggests that the 73 bp deletion in the first intron of the *TP73* gene and different expression levels of ZEB1 and p300 may act in concert to affect the ratio of TAp73/ATAp73 forms, favouring p73 oncogenic variants ([Fig. 2A](#fig02){ref-type="fig"}). In addition, up-regulation of p73 oncogenic isoforms predicts a poor prognosis based on its relationship with advanced tumour stage \[[@b87]\]. However, it is still unclear whether the presence of the deletion increases tumour susceptibility, or whether the effects are seen only on prognosis and further large-scale studies are required. In addition, the influence of this polymorphism on p53 responses are unclear, but might for example be expected to diminish even further the relatively decreased pro-apoptotic ability of the P72 allele of *TP53*, due to an increase in ΔNp73/p73 ratios, enhancing tumour susceptibility. As noted above, in tumours with mutant p53, an opposite effect on prognosis may be seen. To date no studies have investigated these possibilities.

![Polymorphisms in p53 pathways. (**A**) Role of p73 polymorphism. The presence of 73 bp deletion in the first intron of the *TP73* gene is associated with lower levels of p73 but do not affect expression of Δp73 resulting in increased ratio of TAp73/ATAp73 forms, favouring p73 oncogenic variants. (**B**) Role of MDM2 SNP309. Single nucleotide polymorphism 309 in a region of the *MDM2* promoter increases the affinity of the transcriptional activator Sp1, which along with active oestrogen receptors (ER) and genotoxic stress, was found to attenuate the p53 pathways resulting in the acceleration of tumour formation. (**C**) Role of RE polymorphisms. C to T SNP at the Flt-1 promoter creates a p53 binding site resulting in p53-dependent up-regulation of *Flt*-1 transcription in human cells. Active oestrogen receptor signalling considerably enhances this effect.](jcmm0013-0440-f2){#fig02}

Polymorphisms in p53 target genes
=================================

There is clear evidence that increases in the levels of the MDM2 protein attenuate p53 function, leading to cancer formation \[[@b97]\]. A SNP at nucleotide 309 which lies in intron 1 and is within the MDM2 promoter was found to be associated with the attenuation of the p53 pathway and with the acceleration of tumour formation in humans \[[@b98]\]. The SNP changes a T to a G (the G allele is designated SNP309, and occurs at high frequency) creating a higher affinity Sp1 binding site, which is suggested to increase MDM2 mRNA levels ([Fig. 2B](#fig02){ref-type="fig"}). In most publications, the association of MDM2 SNP309 with cancer was connected with the Li-Fraumeni syndrome or with p53 mutational status \[[@b99]\]. Studies associating SNP309 with sporadic cancer risk have provided conflicting results: either no increased risk of breast and ovarian cancer was observed \[[@b102]\] or accelerated tumour and hormone-dependent manner formation was seen in a gender-specific manner \[[@b104]\]. In our study, we could find no association with SNP309 and cancer risk in a series of 158 breast, 17 endometrium, 13 cervix and 45 ovarian cancers. Moreover, we could not find an association of SNP309 with increased MDM2 mRNA, in contrast to previous findings in a small panel of cell lines that indicated an average eightfold higher level of MDM2 mRNA in GG genotype cells \[[@b106]\], nor could we find an increase in MDM2 protein levels in primary tumour material \[[@b107]\]. These data are similar to those seen in mantle cell lymphomas \[[@b108]\]. Thus, neither primary human lymphomas nor the common epithelial malignancies that we studied show a significant role for SNP309 in regulating MDM2 protein levels. We also showed that p53 protein levels were unaffected by SNP309. In summary, the results show no association between SNP309 with breast and other cancer risks, and the presence of G alleles does not increase MDM2 or decrease p53 protein levels in primary human tumours. Thus, the role of MDM2 SNP309 outside of Li-Fraumeni patients is unclear.

A major downstream component of the p53 tumour suppressor pathway is p21 ^af1^, which inhibits progression of the cell cycle from G1 to S phase by inhibiting cyclin-dependent kinases \[[@b109]\]. Mutations in p21 ^a^ are extremely rare; however, several polymorphisms have been described. The polymorphism at codon 31 results in a non-conservative amino-acid change from serine to arginine (S31R). Interestingly, this SNP appears to occur more frequently in cancer patients manifesting wild-type p53 \[[@b110]\]. The frequency of the R allele varies dramatically between major ethnic groups and functional analyses revealed that codon 31 polymorphism does not affect the structure or function of the protein \[[@b111]\]. More recently, Su *et al.* reported that the codon 31 polymorphism alters mRNA expression of p21 ^Waf1^\[[@b112]\]. A number of studies have been performed to examine the involvement of the p21 ^Waf1^ codon 31 polymorphism on cancer susceptibility. Nevertheless, conclusions are inconsistent, as approximately half of these studies support the idea that this polymorphism correlates with cancer risk while others refute this claim \[[@b113]\]. Several studies also examined whether the codon 31 polymorphism may influence cancer prognosis and progression. Studies on a Taiwanese population demonstrated that individuals carrying the S/S genotype had a shorter post-operative survival compared to those with the S/R or R/R genotype \[[@b114]\]. On the other hand, this polymorphism was not found to affect survival in a population of Caucasian Australian breast cancer patients \[[@b115]\].

The S31R polymorphism is also linked to a polymorphism in the 3'UTR of the p21 ^Waf1^ gene. Functionally, the 3'UTR polymorphism may also influence p21 ^Wa^ mRNA stability and the codon 31 polymorphism combined with the polymorphism in the 3'UTR may contribute jointly to the development of squamous cell carcinoma of the head and neck, prostate adenocarcinoma and breast tumours \[[@b110]\].

Considering the fact that p53 binds and transcriptionally regulates several hundreds of genes, it could be expected that many of these genes harbour genetic polymorphisms influencing their function. To labour all of them is outside the remit of this review, therefore only several other examples are mentioned: (i) *PIG3* pentanucleotide microsatellite repeat, which leads to increased p53 inducibility \[[@b117]\]; (ii) 5**'** untranslated region of the *BAX* pro-moter G(-248)A SNP was reported to be associated with both reduced expression of BAX and altered susceptibility to chronic lymphocytic leukaemia \[[@b118]\]; (*iii*) BCL2SNP C(-838)A in the promoter region is responsible for decrease prostate cancer risk \[[@b120]\]; (iv) several SNPs were also reported in FAS gene to be associated with increased risk of breast, cervical, melanoma, lung and other cancers \[[@b121]\].

Polymorphisms in p53 response elements
======================================

The main functions of p53 as a tumour suppressor lie in the ability to transcriptionally regulate genes through binding to the p53 response element. A computational search of SNPs in putative p53 REs in promoter regions identified hundreds of SNPs that alter the sequence of p53 REs \[[@b124]\]. Functional analysis of a small subset of these, including genes with known roles in tumourigen-esis showed that the variant SNPs render the REs less able to mediate p53-induced transcription. Thus, there are numerous genes that are involved in mediating p53 pathway responses that are functionally polymorphic for p53 activation \[[@b125]\]. For example, a C-to-T polymorphism in the VEGF receptor/Flt-1 promoter creates a p53 RE in the less common *Flt*-1T variant (6% of the population) and only this variant induces expression after p53 activation ([Fig. 2C](#fig02){ref-type="fig"}) \[[@b126]\]. Further studies have also demonstrated the critical role for oestrogens identifying the second regulatory sequence within the Flt-1 promoter harbouring a partial response element for oestrogen receptors upstream of the p53 binding site \[[@b127]\]. Their finding suggested that this polymorphism could influence tumour formation/progression in a hormone-sensitive manner. There are no studies to date that have investigated the epidemiology of these SNPs in human cancers, but it seems likely that their influence on the ability to respond to wild-type p53 will affect cancer risk and response to treatment \[[@b125]\].

Concluding remarks
==================

One of the goals of translational oncology is to identify the molecular markers predictive of treatment outcome. Such predictive biomarkers would be of particular value for treatment regimens, such as combined modality therapy, which are associated with severe morbidity and substantial expense, yet produce complete response in only a subset of patients. As such, it is important to find the molecular genetic determinants of treatment outcome to facilitate identification of patients most likely to benefit from such treatments.

p53, a prominent tumour suppressor protein, is a master regulator that targets over a hundred genes for transcriptional up-regulation or repression through sequence-specific interactions with DNA response elements. The precise mechanism by which p53 is inactivated during tumourigenesis may influence its tumour suppressor activity in different ways or to different extents and influence the resulting tumour phenotype. Functionally important polymorphisms in the *TP53* gene exist, as well as the SNPs in p53 response elements of many target genes. The discovery of these individual differences has implications for variation in human responses to environmental stresses, risk of disease, and responsiveness to drug therapies. The data we present in this review suggest that analysis of polymorphism in p53 is one potentially useful marker. Confirmation of the usefulness of analysis of this SNP as a biomarker of treatment outcome should prompt serious consideration of its use in the routine work-up of patients prior to treatment decisions being made. However, as a consequence of the complexity of the p53 pathway, there is a need to perform large-scale studies and use multivariate analyses to identify independent SNPs that are of most value. It is to be hoped that such investigations, together with similar studies of other known genetic variations or relevance to cancer, will inform clinical practice to help in the prevention/early detection of cancer and allow better informed decisions for individualized treatment options.
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